Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal XXXX .

@entity1 @entity32 @entity230 @entity30 @entity1851
BACKGROUND: In case of a loss of response to adalimumab, some @entity1 with @entity30 may derive benefit from increasing the dosing frequency to 40 mg weekly. Efficacy and safety of adalimumab 80 mg weekly remain unknown. METHODS: From February 2011 to September 2012, all adults who had active @entity30 , defined at least by @entity30 activity index >150 and 1 objective sign of @entity32 , and required an adalimumab dose escalation to 80 mg weekly were enrolled in a prospective multicenter cohort study. @entity30 activity index and @entity1851 levels were recorded during the first 14 weeks following adalimumab optimization and at 6 months. All adverse events were recorded. RESULTS: Forty-two @entity1 were included. The median age was 33 years, and the median disease duration was 8.6 years. Adalimumab was associated with @entity230 in 28% of cases and with immunomodulators in 10% of @entity1 . Within the 14 weeks after adalimumab optimization, 14 @entity1 (33.3%) achieved clinical remission ( @entity30 activity index <150), and 23 @entity1 (54.8%) had a clinical response. Clinical improvement was associated with a drop in the @entity1851 level from 18 to 5 mg/L (P = 0.0008). After a median follow-up of 14.5 months, 5 @entity1 underwent major abdominal surgery. Adverse events were reported in 13 @entity1 (31%). CONCLUSIONS: Adalimumab 80 mg weekly seems to be well-tolerated and may be effective in inducing clinical remission in @entity1 with luminal @entity30 who failed to respond to 40 mg weekly or 80 mg every other week.
